WHO guidance on the use of licensed human influenza A(H5) vaccines for the interpandemic and emergence periods

Overview

This WHO guidance document outlines the primary objectives for the use of licensed human A(H5) vaccines for the interpandemic and emergence periods, identifies key factors to support country-level decision-making, describes potential target groups based on risk of exposure, and includes a decision-aid matrix to assist countries in determining A(H5) vaccination approaches under various epidemiological scenarios. This WHO guidance supersedes previous recommendations on the topic and offers updated guidance to support countries in formulating their A(H5) vaccine policies.